Member Info for volcano

The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is £182.53m. The last step is to then divide the equity value by the number of shares outstanding. This results in an intrinsic value estimate of £1.17. Compared to the current share price of £1.08, the company appears about fair value at a 7.1% discount to where the stock price trades currently. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent.

Luceco (LON:LUCE) Now Covered by Peel Hunt
Posted by Amelie Mason on Jul 12th, 2019
Luceco logoPeel Hunt began coverage on shares of Luceco (LON:LUCE) in a report issued on Wednesday, ThisIsMoney.Co.Uk reports. The firm set an “add” rating and a GBX 120 ($1.57) price target on the stock. Peel Hunt’s price objective points to a potential upside of 14.29% from the company’s current price.

Separately, Numis Securities reissued a “buy” rating and issued a GBX 115 ($1.50) price objective on shares of Alliance Pharma in a report on Friday, May 24th.

donotpanic i can buy many as i want to, i don't know who is your broker.

donopanic you must have paid 60p for your shares yesterday , you sound desperate.

Indivior (INDV) shares were up more than a quarter in early trading after the pharmaceutical group raised revenue guidance to between $670m and $720m for 2019, up from $525-$575m, while net income is expected to be between $80m and $130m, from a loss of $40m to profit of $10m (excluding exceptional items and currency). Management attributed the improved guidance to market share outperformance of its branded SUBOXONE Film. However, the opioid addiction treatment specialist remains under investigation by the US Department of Justice over offences including marketing and promotion practices, pediatric safety claims, and overprescribing of medication by certain physicians - charges it denies and is defending itself against.

looks like 9p to start with

Why INDV issued second RNS at one a clock? so many people got sacked in to INDV at 60p . INDV could have issued the both RNS in the morning . WHY not ? they had the facts.

only people made money today are MM

i bought back at 54p

(Reuters) - Britain’s Reckitt Benckiser (RB.L) has agreed to pay up to $1.4 billion to resolve all U.S. federal investigations into the sales and marketing of an opioid addiction treatment by its former prescription pharmaceuticals business Indivior (INDV.L).

have you sold over INDV? , i have sold half of my holdings at 60p .

Reckitt Benckiser Group PLC (LON:RB.) advanced 2.2% to 6,571p after it reached agreements with the US Department of Justice and the Federal Trade Commission to resolve the investigation into the sales of Suboxone Film by its former prescription pharmaceuticals business Indivior.

The company will pay up to US$1.4bn to get the US authorities off its back but the market decided it was a price worth paying to draw line under the affair.

Indivior PLC (LON:INDV), meanwhile, was up by a third at 58.78p after it raised full year revenue and earnings guidance.

Reckitt Benckiser was among the stocks pushing the FTSE 100 higher after agreeing to settle a US probe for USD1.4 billion, while former subsidiary Indivior surged on boosted guidance.

HeresHopin if that wasn't the case why (Reckitt) settles it ? ether-way we could see a £1 here.

The indictment includes twenty-eight felony counts - one count of conspiracy to commit mail, wire and health care fraud; one count of health care fraud; four counts of mail fraud; and twenty-two counts of wire fraud. The allegations are based on actions that occurred almost exclusively prior to Indivior becoming an independent company in its demerger from Reckitt Benckiser Group plc at the end of 2014. The Company believes the allegations are unsupported by the facts and the law. Key allegations have been contradicted by the U.S. government's scientific agencies, the Food and Drug Administration and the Centers for Disease Control.

i said we could see 50p here , not bad 55p now

let it settle ,don't panic

60p to open

could be £1 to open , it is going to be a good day.

Reckitt Benckiser has announced it will pay $1.4bn to resolve US federal investigations linked to Suboxone Film, the opioid-addiction treatment made by Indivior.

The firm has reached the deal with the Department of Justice and the Federal Trade Commission following legal action claiming that Indivior, which was demerged by Reckitt Benckiser in 2014, "deceived" healthcare providers that Suboxone Film was "safer, less divertible and less abusable than other opioid-addiction treatment drugs".

The company said: "While RB has acted lawfully at all times and expressly denies all allegations that it engaged in any wrongful conduct, after careful consideration, the board of RB determined that the agreement is in the best interests of the company and its shareholders."